Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05316493
PHASE2/PHASE3

Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

Sponsor: Xiaojun Chen

View on ClinicalTrials.gov

Summary

To investigate the efficacy of weight management plus levonorgestrel intrauterine system (LNG-IUS) or megestrol acetate (MA) in obese patients with endometrial atypical hyperplasia (EAH) asking for conservative therapy.

Official title: Weight Management Plus Levonorgestrel Intrauterine System or Megestrol Acetate in Endometrial Atypical Hyperplasia: Multiple Single-arm, Prospective and Open-label Clinical Study

Key Details

Gender

FEMALE

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

172

Start Date

2022-06-13

Completion Date

2027-02-28

Last Updated

2025-08-11

Healthy Volunteers

No

Interventions

BEHAVIORAL

Intensive Lifestyle Intervention (ILI)

dietary guidance, exercise guidance, lifestyle intervention

DRUG

Megestrol Acetate 160 MG Oral Tablet

enrolled participants will take Megestrol Acetate 160mg daily

DRUG

Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg

enrolled patients will be treated with LNG-IUS.

Locations (1)

Obstetrics and Gynecology Hospital of Fudan University

Shanghai, China